Search Result

Pathways Recommended:	PI3K/Akt/mTOR

Results for "

PI3K kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PI3K (107) Akt (27) Amino Acid Derivatives (1) Antibiotic (2) Apoptosis (33) Arp2/3 Complex (1) ATM/ATR (6) Autophagy (13) Bcl-2 Family (5) Cadherin (3) Casein Kinase (12) Caspase (3) Cathepsin (1) CDK (8) Choline Kinase (1) Cholinesterase (ChE) (2) Cytochrome P450 (2) DNA-PK (5) DNA/RNA Synthesis (1) EGFR (3) Epigenetic Reader Domain (1) ERK (5) FAK (1) Flavivirus (1) FLT3 (3) FXR (1) G Protein-coupled Receptor Kinase (GRK) (1) Glucose-6-Phosphate Isomerase (GPI) (1) GLUT (1) HBV (2) HSP (1) IFNAR (1) IKK (1) Influenza Virus (2) Integrin (1) Interleukin Related (1) JAK (2) JNK (2) Ligands for Target Protein for PROTAC (1) Lipase (1) MAP4K (1) MEK (2) Mitochondrial Metabolism (2) MMP (3) mTOR (31) NF-κB (7) NOD-like Receptor (NLR) (2) Organoid (2) P-glycoprotein (2) p38 MAPK (9) Parasite (1) PARP (3) PERK (1) PI4K (2) PKC (4) Polo-like Kinase (PLK) (3) PROTACs (3) Raf (3) Ras (2) Reactive Oxygen Species (ROS) (3) Reference Standards (16) RET (2) ROR (1) SphK (1) Src (3) STAT (4) Syk (1) TAM Receptor (2) Trk Receptor (1) VEGFR (3) Virus Protease (1) Wnt (2)
By Research Areas:	Cancer (111) Cardiovascular Disease (6) Infection (10) Inflammation/Immunology (23) Metabolic Disease (10) Neurological Disease (8)
Oligonucleotides:	Phospholipids (1)

126

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Targets Recommended: PI3K

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10108

LY294002 Maximum Cited Publications 1120 Publications Verification	PI3K Casein Kinase DNA-PK Apoptosis Autophagy	Infection Cancer
LY294002 is a broad-spectrum inhibitor of *PI3K* with IC₅₀s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively . LY294002 also inhibits CK2 with an IC₅₀ of 98 nM . LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC₅₀ of 1.4 μM. LY294002 is an apoptosis activator .

HY-10197

Wortmannin Maximum Cited Publications 165 Publications Verification SL-2052; KY-12420	Organoid PI3K Polo-like Kinase (PLK) Autophagy Antibiotic	Cancer
Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible *PI3K* inhibitor with an IC₅₀ of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits *Polo-like kinase* 1 (PlK1) and Plk3 with IC₅₀**s of 5.8 and 48 nM, respectively .

HY-50673

Dactolisib 65+ Cited Publications BEZ235; NVP-BEZ235	PI3K mTOR Autophagy	Cancer
Dactolisib (BEZ235) is an orally active and dual pan-class I *PI3K* and mTOR kinase inhibitor with IC₅₀s of 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for p110α/p110γ/p110δ/p110β and mTOR, respectively. Dactolisib (BEZ235) inhibits both mTORC1 and mTORC2.

HY-100716

Eganelisib 15+ Cited Publications IPI-549	PI3K	Cancer
Eganelisib (IPI549) is a potent and selective PI3Kγ inhibitor with an IC₅₀ of 16 nM. Eganelisib shows >100-fold selectivity over other lipid and protein kinases .

HY-15346

Copanlisib 30+ Cited Publications BAY 80-6946	PI3K Apoptosis	Cancer
Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I *PI3K* inhibitor, with IC₅₀s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity .

HY-15346A

Copanlisib dihydrochloride 30+ Cited Publications BAY 80-6946 dihydrochloride	PI3K Apoptosis	Cancer
Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a potent, selective and ATP-competitive pan-class I *PI3K* inhibitor, with IC₅₀s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib dihydrochloride has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib dihydrochloride has superior antitumor activity .

HY-139609

Camonsertib 2 Publications Verification RP-3500; ATR inhibitor 4	ATM/ATR mTOR	Cancer
Camonsertib (RP-3500) is an orally active, selective ATR kinase inhibitor (ATRi) with an IC₅₀ of 1.00 nM in biochemical assays. Camonsertib shows 30-fold selectivity for ATR over mTOR (IC₅₀=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. Camonsertib has potent antitumor activity .

HY-13246

Apitolisib 10+ Cited Publications GDC-0980; GNE 390; RG 7422	PI3K mTOR Apoptosis	Cancer
Apitolisib (GDC-0980; GNE 390; RG 7422) is a selective, potent, orally bioavailable Class I *PI3* kinase and mTOR kinase (TORC1/2) inhibitor with IC₅₀s of 5 nM/27 nM/7 nM/14 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ, and with a?K_i?of 17 nM for mTOR.

HY-128574

D927 DS11252927	GLUT PI3K Akt	Metabolic Disease
D927 (DS11252927) is an orally active glucose transporter type 4 (GLUT4) translocation activator with an EC₅₀ of 0.14 μM. D927 enhances the binding affinity of PI3Kα catalytic subunit p110α to canonical RAS proteins (KRAS4A, KRAS4B) and RRAS, RRAS2, MRAS. D927 activates the PI3Kα-AKT pathway (increasing phosphorylation of AKT, p70S6 kinase) without affecting the RAF-ERK1/2 pathway. D927 improves hyperglycemia in type 1 and type 2 diabetes mice model. D927 can be used for the study of glucose homeostasis disorders and diabetes .

HY-12279

Umbralisib 5 Publications Verification TGR-1202; RP5264	PI3K Casein Kinase	Cancer
Umbralisib (TGR-1202) is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC₅₀ of 22.2 nM and 6.0 μM, respectively. Umbralisib exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib can be used for haematological malignancies reseach .

HY-100398

PF-04979064 2 Publications Verification	PI3K mTOR	Cancer
PF-04979064 is a potent and selective *PI3K/mTOR* dual kinase inhibitor with K_is of 0.13 nM and 1.42 nM for PI3Kα and mTOR, respectively.

HY-12948

AMG319 1 Publications Verification	PI3K	Cancer
AMG319 is a potent and selective PI3Kδ kinase inhibitor with IC₅₀ of 18 nM.

HY-15174

Dactolisib Tosylate 65+ Cited Publications BEZ235 Tosylate; NVP-BEZ 235 Tosylate	PI3K mTOR Autophagy	Cancer
Dactolisib Tosylate (BEZ235 Tosylate) is a dual *PI3K* and mTOR kinase inhibitor with IC₅₀ values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2.

HY-116035

Nimbolide 2 Publications Verification	Wnt NF-κB CDK Apoptosis	Cancer
Nimbolide is a triterpene compound that can be isolated from neem (Azadirachta indica), possesses anticancer and antiproliferative activity. Nimbolide induces tumor cell apoptosis by inhibiting NF-κB and CDK4/CDK6 kinase. Nimbolide suppresses the Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways .

HY-N2081

Skimmianine 3 Publications Verification	Cholinesterase (ChE) PI3K Akt NF-κB	Neurological Disease Inflammation/Immunology Cancer
Skimmianine is an orally active furoquiniline alkaloid present mainly in the Rutaceae family. Skimmianine has analgesic, antispastic, sedative, and anti-inflammatory properties. Skimmianine inhibits acetylcholinesterase (AChE) (IC₅₀ = 8.6 μg/mL). Skimmianine exhibits cytotoxicity against a variety of cancer cell lines and genotoxicity. Skimmianine has antioxidant and anti-inflammatory effects on ischemia-reperfusion (IR) injury. Skimmianine exerts anti-inflammatory effects through activation of the phosphatidylinositol-3-kinase (PI3K)-protein kinase B (AKT) pathway. Skimmianine is neuroprotective by targeting the NF-κB activation pathway to prevent neuroinflammation. Skimmianine inhibits the release of histamine, intracellular Ca ²⁺ signaling and protein kinase C signaling .

HY-16585

VS-5584 5 Publications Verification SB2343	PI3K mTOR	Cancer
VS-5584 is a *pan-PI3K/mTOR* kinase inhibitor with IC₅₀s of 16 nM, 68 nM, 42 nM, 25 nM, and 37 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively. VS-5584 simultaneously blocks mTORC2 as well as mTORC1.

HY-135827

Roginolisib 1 Publications Verification MSC2360844; IOA-244	PI3K	Inflammation/Immunology Cancer
Roginolisib (MSC2360844; IOA-244) is a potent, orally active and selective PI3Kδ inhibitor, with an IC₅₀ of 145 nM. Roginolisib shows highly selective against a panel of 278 additional kinases .

HY-N5072

Desmethylglycitein 3 Publications Verification 4',6,7-Trihydroxyisoflavone	CDK PI3K PKC	Cancer
Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities. Desmethylglycitein binds directly to CDK1 and CDK2 in vivo, resulting in the suppresses CDK1 and CDK2 activity . Desmethylglycitein is a direct inhibitor of protein kinase C (PKC)α, against solar UV (sUV)-induced matrix matrix metalloproteinase 1 (MMP1) . Desmethylglycitein binds to *PI3K* in an ATP competitive manner in the cytosol, where it inhibits the activity of PI3K and downstream signaling cascades, leading to the suppression of adipogenesis in 3T3-L1 preadipocytes .

HY-10811

GNE-493 2 Publications Verification	PI3K mTOR	Cancer
GNE-493 is a potent, selective, and orally available dual *pan-PI3-kinase/mTOR* inhibitor with IC₅₀s of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR.

HY-11002

CP-466722 4 Publications Verification	ATM/ATR	Cancer
CP-466722 is a rapidly reversible inhibitor of ATM, with an IC₅₀ of 0.41 μM, and has no effects on PI3K or closely related PI3K-like protein kinase (PIKK) family members.

HY-108606

PI-828 2 Publications Verification	PI3K Casein Kinase	Cancer
PI-828 is a dual *PI3K* and *casein kinase* 2 (CK2) inhibitor with IC₅₀s of 173 nM, 149 nM, and 1127 nM for p110α, CK2, and CK2α2** in lipid kinase assay, respectively .

HY-12037

Rigosertib sodium 5+ Cited Publications ON-01910 sodium	Polo-like Kinase (PLK) PI3K Apoptosis	Cancer
Rigosertib sodium (ON-01910 sodium) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the *PI3K/Akt* pathway, promotes the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle . Rigosertib sodium is a selective and non-ATP-competitive inhibitor of PLK1 with an IC₅₀ of 9 nM .

HY-124760

hSMG-1 inhibitor 11e 3 Publications Verification	mTOR PI3K CDK	Cancer
hSMG-1 inhibitor 11e is a potent and selective hSMG-1 kinase inhibitor with an IC₅₀ of <0.05 nM. hSMG-1 inhibitor 11e shows >900-fold selectivity over mTOR (IC₅₀ of 45 nM), PI3Kα/γ (IC₅₀s of 61 nM and 92 nM) and CDK1/CDK2 (IC₅₀s of 32 μM and 7.1 μM) .

HY-131972

PF-06843195	PI3K	Cancer
PF-06843195 is a highly selective PI3Kα inhibitor with an IC₅₀ of 18 nM in Rat1 fibroblasts. The K_is of PF-06843195 for PI3Kα and PI3Kδ in biochemical kinase assay are less than 0.018 nM and 0.28 nM, respectively. PF-06843195 has great suppression of the PI3K/mTOR signaling pathway and durable antitumor efficacy .

HY-12279C

Umbralisib hydrochloride 5 Publications Verification TGR-1202 hydrochloride; RP5264 hydrochloride	PI3K Casein Kinase	Cancer
Umbralisib (TGR-1202) hydrochloride is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC₅₀ of 22.2 nM and 6.0 μM, respectively. Umbralisib hydrochloride exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib hydrochloride can be used for haematological malignancies reseach .

HY-12895

SKI V 1 Publications Verification	SphK PI3K Apoptosis	Cancer
SKI V is a noncompetitive and potent non-lipid *sphingosine kinase* (SPHK; SK) inhibitor with an IC₅₀ of 2 μM for GST-hSK. SKI V potently inhibits PI3K with an IC₅₀ of 6 μM for hPI3k. SKI V decreases formation of the mitogenic second messenger sphingosine-1-phosphate (S1P). SKI V induces apoptosis** and has antitumor activity .

HY-165099

C-8 Ceramide-1-phosphate	Apoptosis PI3K DNA/RNA Synthesis	Metabolic Disease
C-8 Ceramide-1-phosphate is a cell apoptosis inhibitor and a cell survival inducer that can stimulate DNA synthesis and cell division. C-8 Ceramide-1-phosphate can inhibit acidic sphingomyelinase (SMase) and stimulate *PI3-K, which in turn produces PIP3; PIP3 can also inhibit acidic SMase. The C-8 Ceramide-1-phosphate and ceramide can be interconverted in cells through kinase* and phosphatase activity, and maintaining the balance between the two is crucial for cellular and tissue homeostasis .

HY-110193

SPP-86 2 Publications Verification	RET	Cancer
SPP-86 is a potent and selective cell permeable inhibitor of RET tyrosine kinase, with an IC₅₀ of 8 nM. SPP-86 inhibits RET-induced phosphatidylinositide 3-kinases (PI3K)/Akt and MAPK signaling, also inhibits RET-induced estrogen receptorα (ERα) phosphorylation in MCF7 cells . SPP-86 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-139534

ARI-1 1 Publications Verification	ROR Apoptosis Akt mTOR PARP	Cancer
ARI-1 is a receptor tyrosine kinase-like orphan receptor 1 (ROR1) inhibitor. ARI-1 blocks the *PI3K/AKT/mTOR* signaling pathway in a ROR1-dependent manner. ARI-1 upregulates cleaved-PARP and p-P38. ARI-1 induces Apoptosis. ARI-1 has anticancer activity against non-small cell lung cancer .

HY-156406

PITCOIN4 1 Publications Verification	PI3K	Inflammation/Immunology
PITCOIN4 is a highly selective Class II Alpha *PI3K-C2α* inhibitor. PITCOIN4 shows nanomolar inhibition of PI3K-C2α and >100-fold selectivity in a general kinase panel .

HY-124652

TBK1/IKKε-IN-4	IKK	Cancer
TBK1/IKKε-IN-4 is a 6-aminopyrazolopyrimidine derivative and a potent, selective TBK1 and IKKε inhibitor with IC₅₀ values of 13 nM and 59 nM, respectively. TBK1/IKKε-IN-4 shows 100- to 1000-fold less activity against other protein kinases including PDK1, PI3K family members and mTOR .

HY-147419

Vulolisib	PI3K	Cancer
Vulolisib is a potent and orally active phosphatidylinositol 3-kinase (PI3K) inhibitor, with IC₅₀ values of 0.2 nM, 168 nM, 90 nM and 49 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively. Antiproliferative and antineoplastic activity .

HY-10620

PI3K-IN-22	PI3K mTOR	Cancer
PI3K-IN-22 is a PI3Kα/mTOR dual kinase inhibitor. PI3K-IN-22 has IC₅₀s of 0.9, 0.6 nM for PI3Kα and mTOR, respectively. PI3K-IN-22 can be used for the research of cancer .

HY-153120A

PI3K/mTOR Inhibitor-13 sodium	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-13 sodium is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and mTOR kinase. PI3K/mTOR Inhibitor-13 sodium has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .

HY-W005308

N-BOC-DL-serine methyl ester	Amino Acid Derivatives	Cancer
N-BOC-DL-serine methyl ester is a Serine derivative. N-BOC-DL-serine methyl ester is used for the synthesis of α,β-dehydro-α-amino acid. N-BOC-DL-serine methyl ester is also used for the synthesis of anti-cancer agent, such as quinazolinone derivative that inhibits PI3K activity, and tricyclic pyrolopyranopyridines that inhibits protein kinase activity .

HY-15174R

Dactolisib Tosylate (Standard) BEZ235 Tosylate (Standard); NVP-BEZ 235 Tosylate (Standard)	PI3K mTOR Autophagy Reference Standards	Cancer
Dactolisib (Tosylate) (Standard) is the analytical standard of Dactolisib (Tosylate). This product is intended for research and analytical applications. Dactolisib Tosylate (BEZ235 Tosylate) is a dual PI3K and mTOR kinase inhibitor with IC50 values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2.

HY-100603A

(S)-GSK-F1	PI3K PI4K	Infection
(S)-GSK-F1 (Compound 28) is an inhibitor for type III phosphatidylinositol 4-kinase α (PI4KIIIα). (S)-GSK-F1 inhibits PI4Kα, PI4Kβ, PI4Kγ, PI3Kα, PI3Kβ and PI3Kδ with pIC₅₀ of 8.3, 6.0, 5.6, 5.6, 5.1 and 5.6, respectively. (S)-GSK-F1 exhibits anti-hepatitis C virus (HCV) activity through inhibition of HCV replication. (S)-GSK-F1 exhibits moderate pharmacokinetic characters in rat model .

HY-164384

DFX117	PI3K Akt mTOR Apoptosis	Cancer
DFX117 is a selective, orally active inhibitor for PI3Kα and c-Met tyrosine kinase. DFX117 inhibits *PI3K/Akt/mTOR* pathway, inhibits the proliferation of NCI-H1975, NCI-H1993, and HCC827 with IC₅₀s 0.02-0.08 µM. DFX117 arrests cell cycle at G0/G1 phase, induces apoptosis in A549 and NCI-H1975. DFX117 exhibits antitumor efficacy in mice .

HY-137340

WH-10417-099	PROTACs Casein Kinase	Cancer
WH-10417-099 is a CRBN-based PROTAC multi-kinase degrader that induces the degradation of the maximum number of unique kinases (over 125 unique kinases, such as CSNK1E and PI3Kγ) simultaneously. WH-10417-099 induces protein degradation via the ubiquitin biotinylation (E-STUB) pathway, exhibits synergistic effects with SB-405483 (HY-W1135319). The E3 ligase ligand and linker of WH-10417-099 can form the conjugate Pomalidomide 4'-PEG5-acid (HY-131647) .

HY-123849

SN32976	PI3K mTOR	Cancer
SN32976 is a potent and selective class I *PI3K* and mTOR inhibitor with IC₅₀s of 15.1 nM, 461 nM, 110 nM, 134 nM and 194 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ and mTOR, respectively. SN32976 shows high selectivity among other 442 kinases. SN32976 shows anticancer effects .

HY-153120

PI3K/mTOR Inhibitor-13	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-13 is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and mTOR kinase. PI3K/mTOR Inhibitor-13 has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .

HY-131910

IHMT-PI3Kδ-372	PI3K Cytochrome P450	Inflammation/Immunology
IHMT-PI3Kδ-372 is a potent and selective PI3Kδ inhibitor with an IC₅₀ of 14 nM. IHMT-PI3Kδ-372 shows high selectivity over other class I PI3Ks (56～83 fold) and other protein kinases. IHMT-PI3Kδ-372 can be uesd for chronic obstructive pulmonary disease (COPD) research .

HY-161366

OMS14	PI3K	Cancer
OMS14 is exhibits inhibitory activity for phosphoinositide 3-kinase γ (PI3Kγ) and PIK3CD/PIK3R1, which inhibits 19% PI3Kγ and 65% PIK3CD/PIK3R1 activity at 100 μM. OMS14 exhibits anticancer efficacy in various cancer cells .

HY-179457

CC-11	PI3K mTOR Akt HSP	Cancer
CC-11 is an orally active small molecule drug conjugate (SMDC) that links the *PI3K/mTOR* inhibitor with the extracellular heat shock protein 90 (EHSP90) targeting ligand through a cleavable linker. CC-11 exhibits strong HSP90 binding activity (IC₅₀ = 15 nM) and inhibits PI3Kα kinase activity (IC₅₀ = 0.54 nM). CC-11 has anti-proliferative activity against colon cancer cells. CC-11 shows significant efficacy in the HCT-116 xenograft tumor model. CC-11 can be used for research on colon cancer .

HY-142677

PI3K-IN-27	PI3K	Inflammation/Immunology Cancer
PI3K-IN-27 is a potent inhibitor of PI3K. PI3K belongs to a large family of lipid signaling kinase that plays key role in cellular process including cell growth, differentiation, migration and apoptosis. PI3K-IN-27 has the potential for the research of hyper-proliferative diseases like cancer and inflammation, or immune and autoimmune diseases (extracted from patent WO2021233227A1, compound 1) .

HY-15346R

Copanlisib (Standard) 1 Publications Verification BAY 80-6946 (Standard)	Reference Standards PI3K Apoptosis	Cancer
Copanlisib (Standard) is the analytical standard of Copanlisib. This product is intended for research and analytical applications. Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I *PI3K* inhibitor, with IC₅₀s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity .

HY-10108R

LY294002 (Standard)	Reference Standards PI3K Casein Kinase DNA-PK Apoptosis Autophagy	Infection Cancer
LY294002 (Standard) is the analytical standard of LY294002. This product is intended for research and analytical applications. LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively . LY294002 also inhibits CK2 with an IC50 of 98 nM . LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator .

HY-109029

Dezapelisib INCB040093	PI3K	Cancer
Dezapelisib (NCB040093) is a potent inhibitor of phosphatidylinositol 3-kinase δ (PI3Kδ). Dezapelisib is a promising research strategy for select R/R B-cell lymphomas .

HY-147567

ATR-IN-15	ATM/ATR DNA-PK PI3K	Cancer
ATR-IN-15 (compound 1) is an orally active and potent ATR kinase inhibitor, with an IC₅₀ of 8 nM. ATR-IN-15 also inhibits human colon tumor cells LoVo, DNA-PK and *PI3K, with IC₅₀* values of 47, 663 and 5131 nM, respectively .

HY-N5072R

Desmethylglycitein (Standard) 4',6,7-Trihydroxyisoflavone (Standard)	Reference Standards CDK PI3K PKC	Cancer
Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities. Desmethylglycitein binds directly to CDK1 and CDK2 in vivo, resulting in the suppresses CDK1 and CDK2 activity . Desmethylglycitein is a direct inhibitor of protein kinase C (PKC)α, against solar UV (sUV)-induced matrix matrix metalloproteinase 1 (MMP1) . Desmethylglycitein binds to PI3K in an ATP competitive manner in the cytosol, where it inhibits the activity of PI3K and downstream signaling cascades, leading to the suppression of adipogenesis in 3T3-L1 preadipocytes .

Cat. No.	Product Name

HY-L009

Kinase Inhibitor Library

3,849 compounds

Kinase is an enzyme that adds phosphate groups to other molecules. This process is known as phosphorylation. Protein phosphorylation is a key aspect in the regulation of a large number of cellular processes including cellular division, metabolism, signal transduction, and so on. There are over 500 kinases encoded by the human genome and it has been estimated that kinases regulate approximately 50% of cellular functions. Kinases are a large group of drug targets in drug discovery. Kinase inhibitors are an important class of drugs that block certain enzymes involved in diseases such as cancer and inflammatory disorders.

Kinase inhibitor library designed by MCE contains 3,849 kinase inhibitors and regulators mainly targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.) and carbohydrate kinases (Hexokinase), and is a useful tool for kinase drug discovery and related research.

HY-L009M

Kinase Inhibitor Library Mini

270 compounds

Kinases is a class of enzymes that adds chemicals called phosphates to other molecules, such as sugars or proteins. Protein phosphorylation serves as a critical regulatory mechanism for numerous cellular processes including cell division, metabolism, and signal transduction, with approximately 50% of cellular functions in humans being regulated by kinase activity. In drug discovery, kinases represent a major category of therapeutic targets, and kinase inhibitors constitute an important class of pharmaceuticals that block the activity of specific disease-associated enzymes, particularly in cancer and inflammatory disorders. Small molecule kinase inhibitors represent one of the fastest-growing drug categories, having received U.S. Food and Drug Administration (FDA) approval for both oncological and non-oncological indications. As of September 2023, over 70 FDA-approved small molecule kinase inhibitors are commercially available.

The MCE Kinase Inhibitor Library Mini contains 270 kinase inhibitors primarily targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.), and carbohydrate kinases. This collection includes 1-3 highly specific representative compounds per target, optimized for screening of kinase-related drug targets in pharmaceutical research.

HY-L015

PI3K/Akt/mTOR Compound Library

1,049 compounds

The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.

MCE owns a unique collection of 1,049 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

Cat. No.	Product Name	Type

HY-165099

C-8 Ceramide-1-phosphate

Biochemical Assay Reagents

C-8 Ceramide-1-phosphate is a cell apoptosis inhibitor and a cell survival inducer that can stimulate DNA synthesis and cell division. C-8 Ceramide-1-phosphate can inhibit acidic sphingomyelinase (SMase) and stimulate PI3-K, which in turn produces PIP3; PIP3 can also inhibit acidic SMase. The C-8 Ceramide-1-phosphate and ceramide can be interconverted in cells through kinase and phosphatase activity, and maintaining the balance between the two is crucial for cellular and tissue homeostasis .

Cat. No.	Product Name	Target	Research Area

HY-W005308

N-BOC-DL-serine methyl ester	Amino Acid Derivatives	Cancer
N-BOC-DL-serine methyl ester is a Serine derivative. N-BOC-DL-serine methyl ester is used for the synthesis of α,β-dehydro-α-amino acid. N-BOC-DL-serine methyl ester is also used for the synthesis of anti-cancer agent, such as quinazolinone derivative that inhibits PI3K activity, and tricyclic pyrolopyranopyridines that inhibits protein kinase activity .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99463

Batiraxcept 2 Publications Verification AVB-500; AVB-S6-500	TAM Receptor PI3K Akt p38 MAPK	Cancer
Batiraxcept (AVB-500; AVB-S6-500) is a selective, soluble AXL receptor and GAS6 inhibitor that targets the GAS6-AXL signaling axis. Batiraxcept is orally inactive and does not cross the blood-brain barrier. Batiraxcept competitively binds to GAS6 ((K_D <1 nM), preventing its interaction with the AXL receptor tyrosine kinase, thereby inhibiting downstream *PI3K/AKT* and MAPK signaling pathways, reducing tumor cell glycolysis, angiogenesis, and metastatic potential. Batiraxcept has demonstrated antitumor activity in preclinical models of endometrial, cholangiocarcinoma, and ovarian cancer by inhibiting tumor growth, invasion, and metastasis .

Species:	Human (4)
Tag:	His (4) GST (3)
Source:	Sf9 insect cells (4)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P702976

	PIK3R2 Protein, Human (sf9, His) PI3K (p85 beta); Phosphatidylinositol 3-kinase regulatory subunit beta; PI3-kinase regulatory subunit beta; PI3K regulatory subunit beta; PtdIns-3-kinase regulatory subunit beta; Phosphatidylinositol 3-kinase 85 kDa regulatory subunit beta (PI3-kinase subunit p85-beta; PtdIns-3-kinase regulatory subunit p85-beta)	Human	Sf9 insect cells
	PIK3R2 Protein, Human (sf9, His) is the recombinant human-derived PIK3R2, expressed by Sf9 insect cells , with His labeled tag. ,

HY-P701752

	PK3C3 Protein, Human (Active, sf9, His, GST) PIK3C3; Phosphatidylinositol 3-kinase catalytic subunit type 3; PI3-kinase type 3; PI3K type 3; PtdIns-3-kinase type 3; Phosphatidylinositol 3-kinase p100 subunit; Phosphoinositide-3-kinase class 3; hVps34	Human	Sf9 insect cells
	The PI3KC3 protein is the catalytic subunit of the PI3K complex and mediates the formation of phosphatidylinositol 3-phosphate. PI3KC3-C1 initiates autophagosomes, whereas PI3KC3-C2 promotes autophagosome maturation and endocytosis. PK3C3 Protein, Human (sf9, His, GST) is the recombinant human-derived PK3C3 protein, expressed by sf9 insect cells , with N-8*His, N-GST labeled tag.

HY-P701744

	PIK3R3 Protein, Human (sf9, His, GST) 1 Publications Verification PIK3R3; Phosphatidylinositol 3-kinase regulatory subunit gamma; PI3-kinase regulatory subunit gamma; PI3K regulatory subunit gamma; PtdIns-3-kinase regulatory subunit gamma; Phosphatidylinositol 3-kinase 55 kDa regulatory subunit gamma; PI3-kinase subunit p55-gamma; PtdIns-3-kinase regulatory subunit p55-gamma; p55PIK	Human	Sf9 insect cells
	PIK3R3 protein, through its SH2 domain, interacts with phosphorylated protein-tyrosine kinases, crucially regulating their kinase activity. During insulin stimulation, PIK3R3 binds to IRS-1. Operating as a heterodimer with a p110 catalytic subunit, it interacts with AXL, expanding its functional network. PIK3R3 Protein, Human (sf9, His, GST) is the recombinant human-derived PIK3R3 protein, expressed by sf9 insect cells , with N-8*His, N-GST labeled tag.

HY-P703582

	PIK3CG Protein, Human (sf9, His, GST) Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit gamma; PtdIns-3-kinase subunit p110-gamma; p110gamma; Phosphoinositide-3-kinase catalytic gamma polypeptide; Serine/threonine protein kinase PIK3CG; 2.7.11.1; p120-PI3K; PIK3CG; Homo saPIens; Human; PI3-kinase subunit gamma; kinase; Serine/threonine-protein kinase; Transferase; 2.7.1.137	Human	Sf9 insect cells
	PIK3CG Protein, Human (sf9, His, GST) is the recombinant human-derived PIK3CG, expressed by sf9 insect cells , with His, GST labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (5) Rabbit (13)
Reactivity:	Human (17) Rat (17) Mouse (17)
Application:	IHC-P (10) ICC/IF (12) IF-Tissue (1) IP (4) IHC-F (2) WB (18) ELISA (4)
Isotype:	IgG (12) IgG1 (3) IgG/Kappa (1)
Conjugation:	Non-conjugated (18)
Clonality:	Polyclonal (3) Monoclonal (12) Recombinant (6)
Modification:	Phosphorylated (3) Unmodified (12)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P80866

	PI3 Kinase p55 gamma Antibody 1 Publications Verification GRB1; P85A; PI3-kinase p85-alpha subunit; PI3K; PI3K p85-alpha; P55G; PI3-kinase p85-gamma subunit; PI3K p85-gamma	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	PI3 Kinase p55 gamma Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to PI3 Kinase p55 gamma.

HY-P80866A

	PI3 Kinase p55 gamma Antibody (YA4639) GRB1; P85A; PI3-kinase p85-alpha subunit; PI3K; PI3K p85-alpha; P55G; PI3-kinase p85-gamma subunit; PI3K p85-gamma	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	PI3 Kinase p55 gamma Antibody (YA4639) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PI3 Kinase p55 gamma.

HY-P80866AA

	PI3 Kinase p55 gamma Antibody (YA4639)(PBS only) GRB1; P85A; PI3-kinase p85-alpha subunit; PI3K; PI3K p85-alpha; P55G; PI3-kinase p85-gamma subunit; PI3K p85-gamma	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	PI3 Kinase p55 gamma Antibody (YA4639) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PI3 Kinase p55 gamma.

HY-P80865

	PI3 Kinase p110 gamma Antibody (YA690) 1 Publications Verification PI3K; PIK3; PI3CG; PI3Kgamma; p110gamma; p120-PI3K	WB	Human
	PI3 Kinase p110 gamma Antibody (YA690) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PI3 Kinase p110 gamma.

HY-P80867

	PI3 Kinase p85 alpha Antibody (YA689) 3 Publications Verification PIK3R1; GRB1; Phosphatidylinositol 3-kinase regulatory subunit alpha; PI3-kinase regulatory subunit alpha; PI3K regulatory subunit alpha; PtdIns-3-kinase regulatory subunit alpha; Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha; PI3-kinase s	WB, IHC-P	Human, Mouse, Rat
	PI3 Kinase p85 alpha Antibody (YA689) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PI3 Kinase p85 alpha.

HY-P80846

	Phospho-PI3 Kinase p85/p55 (Tyr467/Tyr199) Antibody Maximum Cited Publications 8 Publications Verification PIK3R1; GRB1; Phosphatidylinositol 3-kinase regulatory subunit alpha; PI3-kinase regulatory subunit alpha; PI3K regulatory subunit alpha; PtdIns-3-kinase regulatory subunit alpha; Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha; PI3-kinase s	WB, IHC-F, IHC-P, ICC/IF, ELISA	Human, Mouse, Rat
	Phospho-PI3 Kinase p85/p55 (Tyr467/Tyr199) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Phospho-PI3 Kinase p85/p55 (Tyr467/Tyr199).

HY-P810696

	Phospho-PI3 Kinase p85/p55 (Tyr458/Tyr199) Antibody (YA9946) PIK3R1; GRB1; Phosphatidylinositol 3-kinase regulatory subunit alpha; PI3-kinase regulatory subunit alpha; PI3K regulatory subunit alpha; PtdIns-3-kinase regulatory subunit alpha; Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha; PI3-kinase s	WB, ELISA, IF-Tissue	Human, Mouse, Rat
	Phospho-PI3 Kinase p85/p55 (Tyr458/Tyr199) Antibody (YA9946) is a Rabbit-derived and non-conjugated IgG Recombinant monoclonal antibody, targeting to Phospho-PI3 Kinase p85/p55 (Tyr458/Tyr199).

HY-P80867A

	PI3 Kinase p85 alpha Antibody (YA689)(PBS only) PIK3R1; GRB1; Phosphatidylinositol 3-kinase regulatory subunit alpha; PI3-kinase regulatory subunit alpha; PI3K regulatory subunit alpha; PtdIns-3-kinase regulatory subunit alpha; Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha; PI3-kinase s	WB, IHC-P	Human, Mouse, Rat
	PI3 Kinase p85 alpha Antibody (YA689) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PI3 Kinase p85 alpha.

HY-P85740

	PI3 Kinase p85 alpha Antibody (YA5432) PIK3R1; GRB1; Phosphatidylinositol 3-kinase regulatory subunit alpha; PI3-kinase regulatory subunit alpha; PI3K regulatory subunit alpha; PtdIns-3-kinase regulatory subunit alpha; Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha; PI3-kinase subunit p85-alpha; PtdIns-3-kinase regulatory subunit p85-alpha	WB, IHC-P, ICC/IF	Rat, Mouse
	PI3 Kinase p85 alpha Antibody (YA5432) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to PI3 Kinase p85 alpha.

HY-P86645

	PI3 Kinase p85 alpha Antibody (YA6337) PIK3R1; GRB1; Phosphatidylinositol 3-kinase regulatory subunit alpha; PI3-kinase regulatory subunit alpha; PI3K regulatory subunit alpha; PtdIns-3-kinase regulatory subunit alpha; Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha; PI3-kinase subunit p85-alpha; PtdIns-3-kinase regulatory subunit p85-alpha	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	PI3 Kinase p85 alpha Antibody (YA6337) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PI3 Kinase p85 alpha.

HY-P83044

	PI3 Kinase Class 3 Antibody (YA2789) Phosphatidylinositol 3-kinase catalytic subunit type 3 (EC:2.7.1.137); PI3-kinase type 3; PI3K type 3; PtdIns-3-kinase type 3; Phosphatidylinositol 3-kinase p100 subunit; Phosphoinositide-3-kinase class 3; hVps34; VPS34 antibodyPIK3C3;	WB, IHC-P	Human, Mouse, Rat
	PI3 Kinase Class 3 Antibody (YA2789) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PI3 Kinase Class 3.

HY-P81211

	phospho-PI3 Kinase p110 beta (Ser1070) Antibody 5+ Cited Publications PI3-kinase p110 subunit beta; p-PI3Kβ(Ser1070); PI 3-kinase C2β; p110 BETA; p110Beta; Phosphatidylinositol 3 kinase catalytic beta polypeptide; Phosphatidylinositol 4 5 bisphosphate 3 kinase 110 kDa catalytic subunit beta; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit beta isoform; Phosphatidylinositol-4; Phosphoinositide 3 kinase catalytic beta polypeptide; PI3 kinase p110 subunit beta; PI3-kinase subunit beta; PI3K; PI3K beta; PI3K-beta; PI3Kbeta; PI3KCB; PIK3C1; PIk3cb; PK3CB_HUMAN; PtdIns 3 kinase p110; PtdIns-3-kinase subunit beta; PtdIns-3-kinase subunit p110-beta; 5-bisphosphate 3-kinase 110 kDa catalytic subunit beta; 5-bisphosphate 3-kinase catalytic subunit beta isoform.	WB, IHC-P, IHC-F, ICC/IF	Human, Mouse, Rat
	phospho-PI3 Kinase p110 beta (Ser1070) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to phospho-PI3 Kinase p110 beta (Ser1070).

HY-P85585

	PI3 Kinase p85 beta Antibody (YA5277) p85; p85 beta; p85-BETA; P85B; P85B_HUMAN; Phosphatidylinositol 3 kinase; Phosphatidylinositol 3 kinase regulatory beta subunit; Phosphatidylinositol 3 kinase regulatory subunit beta; Phosphatidylinositol 3 kinase regulatory subunit polypeptide 2; Phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 2; p85 beta; Phosphatidylinositol 3-kinase 85 kDa regulatory subunit beta; phosphatidylinositol 3-kinase; Phosphatidylinositol 3-kinase regulatory beta subunit; Phosphatidylinositol 3-kinase regulatory subunit beta; Phosphoinositide 3 kinase regulatory subunit 2; beta; Phosphoinositide 3 kinase regulatory subunit 2; Phosphoinositide 3 kinase regulatory subunit polypeptide 2; p85 beta; Phosphoinositide 3 kinase regulatory subunit polypeptide 2; Phosphoinositide 3 kinase, regulatory subunit 2; beta; Phosphoinositide 3 kinase, regulatory subunit 2; p85 beta; PI3 kinase p85 beta subunit; PI3 kinase p85 subunit beta; PI3-kinase regulatory subunit beta; PI3-kinase subunit p85-beta; PI3K; PI3K regulatory subunit beta; PIK3R 2; PIK3R2; polypeptide 2; p85 beta; PtdIns 3 kinase p85 beta; PtdIns-3-kinase p85-beta; PtdIns-3-kinase regulatory subunit beta; PtdIns-3-kinase regulatory subunit p85-beta.	WB	Human, Mouse, Rat
	PI3 Kinase p85 beta Antibody (YA5277) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to PI3 Kinase p85 beta.

HY-P81162

	PI3 Kinase p110 alpha/PIK3CA Antibody (YA3537) PI3 kinase p110 subunit alpha; caPI3K; MGC142161; MGC142163; p110 alpha; Phosphatidylinositol 3 kinase catalytic alpha polypeptide; Phosphatidylinositol 3 kinase catalytic 110 KD alpha; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform; Phosphoinositide 3 kinase catalytic alpha polypeptide; PI3 kinase p110 subunit alpha; PI3K; PI3KC A; PIK3C A; PK3CA; PtdIns 3 kinase p110; PI3-kinase P110α; PI3-kinase p110 subunit alpha; PI 3 kinase catalytic subunit alpha; PK3CA_HUMAN; PI3 kinase P110α.	WB, ICC/IF, IP	Human, Mouse, Rat
	PI3 Kinase p110 alpha/PIK3CA Antibody (YA3537) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PI3 Kinase p110 alpha/PIK3CA.

HY-P81162A

	PI3 Kinase p110 alpha/PIK3CA Antibody (PBS only) PI3 kinase p110 subunit alpha; caPI3K; MGC142161; MGC142163; p110 alpha; Phosphatidylinositol 3 kinase catalytic alpha polypeptide; Phosphatidylinositol 3 kinase catalytic 110 KD alpha; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform; Phosphoinositide 3 kinase catalytic alpha polypeptide; PI3 kinase p110 subunit alpha; PI3K; PI3KC A; PIK3C A; PK3CA; PtdIns 3 kinase p110; PI3-kinase P110α; PI3-kinase p110 subunit alpha; PI 3 kinase catalytic subunit alpha; PK3CA_HUMAN; PI3 kinase P110α.	WB, ICC/IF, IP	Human, Mouse, Rat
	PI3 Kinase p110 alpha/PIK3CA Antibody (PBS only) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PI3 Kinase p110 alpha/PIK3CA.

HY-P86078

	PI3 Kinase p110 alpha/PIK3CA Antibody (YA5770) 5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha; 5-bisphosphate 3-kinase catalytic subunit alpha isoform; caPI3K; CLOVE; CWS5; MCAP; MCM; MCMTC; MGC142161; MGC142163; p110 alpha; p110alpha; Phosphatidylinositol 3 kinase catalytic alpha polypeptide; Phosphatidylinositol 3 kinase catalytic 110 KD alpha; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform; Phosphatidylinositol 4,5 bisphosphate 3 kinase 110 kDa catalytic subunit alpha; Phosphatidylinositol-4; Phosphoinositide 3 kinase catalytic alpha polypeptide; PI 3 kinase catalytic subunit alpha; PI3 kinase p110 subunit alpha; PI3-kinase subunit alpha; PI3K; PI3K-alpha; PI3KC A; PIK3C A; PIk3ca; PK3CA; PK3CA_HUMAN; PtdIns 3 kinase p110; PtdIns-3-kinase subunit alpha; PtdIns-3-kinase subunit p110-alpha; Serine/threonine protein kinase PIK3CA	WB, ICC/IF, IP, ELISA	Human, Mouse, Rat
	PI3 Kinase p110 alpha/PIK3CA Antibody (YA5770) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PI3 Kinase p110 alpha/PIK3CA.

HY-P81872

	PI3 Kinase p110 delta Antibody (YA1617) PIK3CD; Phosphatidylinositol 4; 5-bisphosphate 3-kinase catalytic subunit delta isoform; PI3-kinase subunit delta; PI3K-delta; PI3Kdelta; PtdIns-3-kinase subunit delta; Phosphatidylinositol 4; 5-bisphosphate 3-kinase 110 kDa catalytic subunit delta; PtdIns-3-kinase subunit p110-delta; p110delta	WB, ICC/IF	Human, Mouse, Rat
	PI3 Kinase p110 delta Antibody (YA1617) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PI3 Kinase p110 delta.

HY-P81872A

	PI3 Kinase p110 delta Antibody (YA1617)(PBS only) PIK3CD; Phosphatidylinositol 4; 5-bisphosphate 3-kinase catalytic subunit delta isoform; PI3-kinase subunit delta; PI3K-delta; PI3Kdelta; PtdIns-3-kinase subunit delta; Phosphatidylinositol 4; 5-bisphosphate 3-kinase 110 kDa catalytic subunit delta; PtdIns-3-kinase subunit p110-delta; p110delta	WB, ICC/IF	Human, Mouse, Rat
	PI3 Kinase p110 delta Antibody (YA1617) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PI3 Kinase p110 delta.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-157706

PI(3,4)P2 (18:1) ammonium salt		Phospholipids
PI(3,4)P2 (18:1) ammonium salt is a phosphatidylinositol 3 kinase (PI3K) activator. PI(3,4)P2 (18:1) ammonium salt is a polyphosphorylated phosphatidylinositol that promotes the activation of AKT (protein kinase B) by activating *PI3K*, which affects cell metabolism, growth and survival. PI(3,4)P2 (18:1) ammonium salt is also involved in regulating dynamic changes in the cytoskeleton, affecting cell morphology and movement. PI(3,4)P2 (18:1) ammonium salt can be used in research on the development of cancer, diabetes and cardiovascular disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

PI3K kinase

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Antibodies

Oligonucleotides

Natural
Products